Journal Mobile Options
Table of Contents
Vol. 88, No. 3, 2012
Issue release date: April 2012
Section title: Review
Free Access
Urol Int 2012;88:249–258

Value of Current Chemotherapy and Surgery in Advanced and Metastatic Bladder Cancer

Racioppi M. · D’Agostino D. · Totaro A. · Pinto F. · Sacco E. · D’Addessi A. · Marangi F. · Palermo G. · Bassi P.F.
Department of Urology, Catholic University of the Sacred Heart, Rome, Italy
email Corresponding Author

Dr. Daniele D’Agostino

Department of Urology, Catholic University of the Sacred Heart

Largo A. Gemelli, 2

IT–00168 Rome (Italy)

Tel. +39 063 015 5290, E-Mail


  1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
  2. International Agency for Research on Cancer (IARC): Cancer Incidence in Five Continents. Vol. 8. IARC Scientific Publication 155. Lyon, IARC Press, 2002.
  3. Bassi P, Ferrante GD, Piazza N, et al: Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161:1494–1497.
  4. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–675.
  5. Dalbagni G, Genega E, Hashibe M, et al: Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111–1116.
  6. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A: Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997;158:393–399.
  7. Hussain SA, James ND: The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003;4:489–497.
    External Resources
  8. Sternberg CN, Yagoda A, Scher HI, et al: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133:403–407.
  9. Sternberg CN, Yagoda A, Scher HI, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989;64:2448–2458.
  10. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985;3:1463–1470.
  11. Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A: Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67:1525–1531.
  12. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066–1073.
  13. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJS, Trump D: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564–2569.
  14. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173–3181.
  15. Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Diaz-Rubio E, Cortés-Funes H, Baselga J, Spanish Oncology Genitourinary Group: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002;95:751–757.
  16. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602–4608.
  17. Lin CC, Hsu CH, Huang CY, et al: Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Urology 2007;69:479–484.
    External Resources
  18. Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG: p53 and treatment of bladder cancer. Nature 1997;385:123–125.
  19. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983–991.
  20. Bellmunt J, Paz-Ares L, Cuello M, et al: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522–528.
  21. Logothetis CJ, Samuels ML, Selig DE, Wallace S, Johnson DE: Combined intravenous and intra-arterial cyclophosphamide, doxorubicin and cisplatin in the management of select patients with invasive urothelial tumours. Cancer Treat Rep 1985;69:33–38.
  22. Sternberg CN, Scher HI: Management of invasive bladder neoplasm; in Smith PH (ed): Combination Therapy in Urological Malignancy. London, Springer, 1989, pp 95–118.
  23. Dodd PM, McCaffrey JA, Herr H, et al: Outcome of post-chemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Clin Oncol 1999;17:25–46.
  24. Ikeda M, Atsumoto K, Niibe Y: The radiotherapy with methotrexate, vimblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer. J Radiat Res 2011;52:674–679.
  25. Sternberg CN: Gemcitabine in bladder cancer. Semin Oncol 2000;27:31–39.
  26. Gebbia V, Testa A, Borsellino N, Mauceri G, Varvara F, Tirrito ML, Sambataro D, Fallica G: Single agent 2′,2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 1999;150:11–15.
  27. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M, De Lena M: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998;34:1208–1212.
  28. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997;15:3441–3445.
  29. Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994;5:182–184.
  30. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394–3398.
  31. Kaufman D, Raghavan D, Carducci M, et al: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000;18:1921–1927.
  32. Moore MG, Winquist MW, Murray N, et al: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of National Cancer Institute of Canada clinical trials. J Clin Oncol 1999;17:2876–2881.
  33. von der Maase H, Andersen L, Crino L, et al: Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of urothelium: a phase II clinical trial. Ann Oncol 1999;10:1461–1465.
  34. Stadler WM, Hayden A, von der Maase H, et al: Long term survival in phase II trial of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002;7:153–157.
  35. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–3077.
  36. Dash A, Pettus JA, Bochner BH, et al: Efficacy of neoadjuvant gemcitabine plus cisplatin in muscle invasive urothelial cancer. J Clin Oncol 2007;25(suppl 18):5077.
  37. Borut K, Lijana ZK: Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer. Radiother Oncol 2011, Epub ahead of print.
  38. Pazdur R, Kudelka A, Kavanagh J, Cohen P, Raber M: The taxoids: paclitaxel (taxol) and docetaxel (taxotere). Cancer Treat Rev 1993;19:351–386.
  39. Roth BJ, Dreicer R, Einhorn LH: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264–2270.
  40. Papamichael D, Gallagher CJ, Oliver RT, Johnson RT, Waxman J: Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997;75:606–607.
  41. de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J: Docetaxel (taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy pretreated patients. Br J Cancer 1998;78:1342–1345.
  42. Dimopoulos MA, Deliveliotis C, Moulopoulos LA, Papadimitriou C, Mitropoulos D, Anagnostopoulos A, Athanassiades P, Dimopoulos C: Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 1998;52:56–60.
  43. McCaffrey JA, Hilton S, Mazumdar M: Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997;15:1853–1857.
  44. Logothetis CJ, Dexeus FH, Finn L, et al: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050–1055.
  45. Sengelov L, Kamby C, Lund B, et al: Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998;16:3392–3397.
  46. Pectasides D, Glotsos J, Bountouroglou N, et al: Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 2002;13:243–250.
  47. Bellmunt J, von der Maase H, Mead GM, et al: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic urothelial cancer without prior systemic therapy; EORTC 30987/Intergroup Study. ASCO annual meeting proceedings. J Clin Oncol 2007;25(suppl 18):LBA 5030.
  48. Seligman PA, Crawford ED: Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 1991;83:1582–1584.
  49. Takahashi T, Higashi S, Nishiyama H, Segawa T, Nakamura E, Kinoshita H, Itoh N, Yamamoto S, Kamoto T, Habuchi T, Ogawa O: Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J Clin Oncol 2006;36:104–108.
  50. Suyama T, Ueda T, Fukasawa S, Imamura Y, Nakamura K, Miyasaka K, Sazuka T, Egoshi K, Nihei N, Hamano M, Ichikawa T, Maruoka M: Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 2009;39:244–250.
    External Resources
  51. Culine S, Theodore C, De Santis M, et al: A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006;94:1395–1401.
  52. Vaughn DJ, Srinivas S, Stadler WM, et al: Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009;115:4110–4117.
  53. Gerullis H, Ecke TH, Janusch B, Arndt C, Heidari M, Ontani J, Otto T: Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance. Anticancer Drugs 2011;22:940–943.
  54. Ohlmann CH, Stöckle M: When should systemic chemotherapy be used for urinary bladder carcinoma? Urologe A 2011, Epub ahead of print.
  55. Herr HW, Donat SM, Barjorin DF, et al: Postchemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165:811–814.
  56. Vieweg J, Gschwend JE, Herr HW, Fair WR: Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449–454.
  57. Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE: Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic node lymphadenectomy. J Urol 2001;166:19–23.
  58. Herr HW, Donat M: Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol 2001;165:62–64.
  59. Yafi FA, Duclos M, Correa JA, Tanguay S, Aprikian AG, Cury F, Souhami L, Rajan R, Kassouf W: Contemporary outcome and management of patients who had an aborted cystectomy due to unresectable bladder cancer. Urol Oncol 2011;29:309–313.
    External Resources
  60. Lehmann J, Suttman H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M: Surgery for metastatic urothelial carcinoma with curative intent. The German experience (AUO AB 30/05). Eur Urol 2009;55:1293–1299.
    External Resources
  61. Sweeney P, Millikan RE, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL: Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection (RPLND) in metastatic transitional cell carcinoma (TCC) of the bladder? J Urol 2003;169:2113–2117.
  62. Otto T, Krege S, Suhr J, Rubben H: Impact of surgical resection of bladder cancer metastases refractory to systemic therapy on performance score: a phase II trial. Urology 2001;57:55–59.
  63. Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, Nonomura K: Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 2007;52:1106–1113.
    External Resources
  64. Skinner DG, Daniels JR, Russell CA, et al: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459–467.
  65. Stockle M, Meyenburg W, Wellek S, et al: Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302–307.
  66. Otto T, Borgemann C, Krege S, et al: Adjuvant chemotherapy in locally advanced bladder cancer (pT3/pN1–2,M0) – A phase III study. Eur Urol 2001;39(suppl 5):147.
  67. Troner M, Birch R, Omura GA, Williams S: Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. J Urol 1987;137:660–662.